{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:33:31Z","timestamp":1794623611514,"version":"4.9.1"},"reference-count":16,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Asparaginase-associated pancreatitis (AAP) is a significant complication in pediatric acute lymphoblastic leukemia (ALL) therapy, often leading to treatment delays or discontinuation. This study aimed to identify AAP risk factors, assess outcomes after first and second episodes, and evaluate the impact of asparaginase rechallenge. We retrospectively analyzed 7640 patients (aged 1 month to 18 years) treated under the Chinese Children Cancer Group ALL 2015 protocol. Patients were stratified as low risk (LR), intermediate risk (IR), or high risk (HR) based on clinical features and measurable residual disease (MRD). AAP was categorized as early or late onset depending on treatment phase. Older age and IR\/HR status were independent risk factors for AAP. The cumulative AAP incidence was 2.2% in LR and 5.8% in IR\/HR groups. Among 298 patients who developed AAP, 92 were rechallenged with asparaginase; second episodes occurred in 20.8% of LR and 33.8% of IR\/HR patients, with no increase in severity. Lack of rechallenge and day 46 MRD of \u22650.01% were independently associated with inferior event-free survival (EFS). Among patients with early-onset AAP, those who were rechallenged had superior 5-year EFS than those who were not rechallenged (80.1% vs 60.2%; P = .003). Similarly, among IR\/HR group, those who were rechallenged had better 5-year EFS than those who were not rechallenged (82.4% vs 60.6%; P = .004). IR\/HR patients with early-onset AAP who were not rechallenged had especially poor outcomes (5-year EFS, 53.3%). These findings support considering asparaginase rechallenge in IR\/HR patients with early-onset AAP when alternative therapies are limited. This trial was registered at www.chictr.org.cn as #ChiCTR2000032211.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025029785","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T19:04:54Z","timestamp":1754939094000},"page":"2417-2427","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Risk factors and outcomes of asparaginase-associated pancreatitis in pediatric patients with ALL"],"prefix":"10.1182","volume":"146","author":[{"given":"Changcheng","family":"Chen","sequence":"first","affiliation":[{"name":"1Department of Hematology\/Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine, National Health Committee Key Laboratory of Pediatric Hematology and Oncology, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2051-4044","authenticated-orcid":false,"given":"Jiaoyang","family":"Cai","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine, National Health Committee Key Laboratory of Pediatric Hematology and Oncology, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuedong","family":"Wu","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Hu","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wu","sequence":"additional","affiliation":[{"name":"4Department of Pediatrics, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Guo","sequence":"additional","affiliation":[{"name":"5Department of Pediatrics, West China Second University Hospital, Sichuan University, Key Laboratory of Birth Defects and Related Disease of Women and Children, Ministry of Education, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyan","family":"Hu","sequence":"additional","affiliation":[{"name":"6Department of Hematology\/Oncology, Children's Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Zhai","sequence":"additional","affiliation":[{"name":"7Department of Hematology\/Oncology, Children's Hospital of Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benquan","family":"Qi","sequence":"additional","affiliation":[{"name":"8Department of Pediatrics, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4156-8332","authenticated-orcid":false,"given":"Weina","family":"Zhang","sequence":"additional","affiliation":[{"name":"9Department of Hematology\/Oncology, Guangzhou Women and Children's Medical Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningling","family":"Wang","sequence":"additional","affiliation":[{"name":"10Department of Pediatrics, Anhui Medical University Second Affiliated Hospital, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengling","family":"Xu","sequence":"additional","affiliation":[{"name":"11Department of Hematology\/Oncology, Chongqing Medical University Affiliated Children's Hospital, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-6471","authenticated-orcid":false,"given":"Yongjun","family":"Fang","sequence":"additional","affiliation":[{"name":"12Department of Hematology\/Oncology, Children's Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2810-5758","authenticated-orcid":false,"given":"Chi-kong","family":"Li","sequence":"additional","affiliation":[{"name":"13Department of Pediatrics, Hong Kong Children\u2019s Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changda","family":"Liang","sequence":"additional","affiliation":[{"name":"14Department of Hematology\/Oncology, Jiangxi Provincial Children's Hospital, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhen","family":"Wang","sequence":"additional","affiliation":[{"name":"15Department of Pediatrics, Affiliated Hospital of Qingdao University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiashi","family":"Zhu","sequence":"additional","affiliation":[{"name":"16Department of Hematology\/Oncology, Children's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Deng","sequence":"additional","affiliation":[{"name":"17Department of Pediatrics, Xiangya Hospital Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tian","sequence":"additional","affiliation":[{"name":"18Department of Hematology\/Oncology, KunMing Children\u2019s Hospital, Kunming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Ju","sequence":"additional","affiliation":[{"name":"19Department of Pediatrics, Qilu Hospital of Shandong University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[{"name":"20Department of Hematology\/Oncology, Xi'an Northwest Women's and Children's Hospital, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyan","family":"Tang","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine, National Health Committee Key Laboratory of Pediatric Hematology and Oncology, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Cheng","sequence":"additional","affiliation":[{"name":"21Department of Biostatistics, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[{"name":"22Department of Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0001-642X","authenticated-orcid":false,"given":"Shuhong","family":"Shen","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine, National Health Committee Key Laboratory of Pediatric Hematology and Oncology, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0303-5658","authenticated-orcid":false,"given":"Ching-Hon","family":"Pui","sequence":"additional","affiliation":[{"name":"23Departments of Oncology, Global Pediatric Medicine, and Pathology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"18","key":"2025111311213612800_bib1","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1200\/JCO.2015.64.5812","article-title":"Clinical and genetic risk factors for acute pancreatitis in patients with acute lymphoblastic leukemia","volume":"34","author":"Liu","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025111311213612800_bib2","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood-2009-09-245951","article-title":"Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia","volume":"115","author":"Silverman","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2025111311213612800_bib3","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/bjh.12733","article-title":"Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol","volume":"165","author":"Raja","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"2025111311213612800_bib4","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.12407","article-title":"Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003","volume":"162","author":"Samarasinghe","year":"2013","journal-title":"Br J Haematol"},{"issue":"2","key":"2025111311213612800_bib5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.19.02208","article-title":"Asparaginase-associated pancreatitis in acute lymphoblastic leukemia: results from the NOPHO ALL2008 treatment of patients 1-45 years of age","volume":"38","author":"Rank","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025111311213612800_bib6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/pbc.22076","article-title":"Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis","volume":"53","author":"Kearney","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"2025111311213612800_bib7","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/MCG.0000000000000827","article-title":"Risk factors for asparaginase-associated pancreatitis: a systematic review","volume":"51","author":"Oparaji","year":"2017","journal-title":"J Clin Gastroenterol"},{"issue":"11","key":"2025111311213612800_bib8","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/MPH.0b013e3181b87035","article-title":"Acute pancreatitis in children with acute lymphoblastic leukemia after chemotherapy","volume":"31","author":"Treepongkaruna","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"issue":"9","key":"2025111311213612800_bib9","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S1470-2045(17)30424-2","article-title":"Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study","volume":"18","author":"Wolthers","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025111311213612800_bib10","doi-asserted-by":"crossref","first-page":"1472049","DOI":"10.3389\/fonc.2024.1472049","article-title":"Effects of asparaginase-associated pancreatitis in children with haematological tumours","volume":"14","author":"Tang","year":"2024","journal-title":"Front Oncol"},{"issue":"4","key":"2025111311213612800_bib11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood.2020010438","article-title":"Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation","volume":"138","author":"Tang","year":"2021","journal-title":"Blood"},{"key":"2025111311213612800_bib12","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute\n          . Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. Accessed 14 August 2025. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"issue":"9","key":"2025111311213612800_bib13","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/S1470-2045(21)00328-4","article-title":"Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial [published correction appears in Lancet Oncol. 2021;22(9):e389]","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"issue":"17","key":"2025111311213612800_bib14","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1182\/blood.2024026381","article-title":"Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL","volume":"145","author":"Zhang","year":"2025","journal-title":"Blood"},{"issue":"17","key":"2025111311213612800_bib15","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025111311213612800_bib16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.23.01392","article-title":"Blinatumomab for first-line treatment of children and young persons with B-ALL","volume":"42","author":"Hodder","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2025029785\/2420035\/blood_bld-2025-029785-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2025029785\/2420035\/blood_bld-2025-029785-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T16:21:42Z","timestamp":1763050902000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/20\/2417\/546602\/Risk-factors-and-outcomes-of-asparaginase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":16,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,11,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025029785","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,13]]},"published":{"date-parts":[[2025,11,13]]}}}